CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing advanced gene therapy vectors, specifically intelligent adenovirus vectors, to improve the delivery and efficacy of gene therapies for diseases with limited treatment options. By leveraging expertise from multiple countries, the project aims to create tailored vectors for targeted app…
Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist.
Efficient gene transfer is inherently and intransigently linked to vector efficacy.
Partially due to the lack of suitable delivery systems for particular applications, the success of too many gene therapies is limited.
Over the last two decades, immense progress has been made in the development of viral vectors.
Importantly, this progress has also identified vector charac…
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Montpellier
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Leiden
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Janssen Vaccines (f.k.a. Crucell Holland B.V.)
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
